Cara Therapeutic Stock In The News
CARA Stock | USD 0.91 0.04 4.60% |
The tone or emotional content of news articles related to Cara Therapeutic can affect its prices. Positive news sentiment can lead to an increase in demand for Cara Therapeutic's stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Cara Therapeutic's news coverage and content from conventional and social sources shows investors' bearish mood towards Cara Therapeutic. The specific impact of Cara Therapeutic news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Cara Therapeutic's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Cara Therapeutic headlines in addition to utilizing other, more conventional financial analysis modules. Check out Cara Therapeutic Backtesting and Cara Therapeutic Hype Analysis. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.
Cara |
Cara Therapeutic Today Top News and Investor Outlook
Cara Therapeutic Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Cara and other traded companies coverage. We help investors stay connected with Cara headlines for the 29th of March to make an informed investment decision based on correlating the impacts of news items on Cara Stock performance. Please note that trading solely based on the Cara Therapeutic hype is not for everyone as timely availability and quick action are needed to avoid losses.Cara Therapeutic stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Cara earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Cara Therapeutic that are available to investors today. That information is available publicly through Cara media outlets and privately through word of mouth or via Cara internal channels. However, regardless of the origin, that massive amount of Cara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cara Therapeutic news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cara Therapeutic relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cara Therapeutic's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cara Therapeutic alpha.
Cara Largest EPS Surprises
Earnings surprises can significantly impact Cara Therapeutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2017-11-02 | 2017-09-30 | -0.34 | -0.38 | -0.04 | 11 | ||
2016-11-03 | 2016-09-30 | -0.47 | -0.42 | 0.05 | 10 | ||
2019-03-12 | 2018-12-31 | -0.58 | -0.52 | 0.06 | 10 | ||
2016-08-04 | 2016-06-30 | -0.42 | -0.48 | -0.06 | 14 | ||
2015-05-12 | 2015-03-31 | -0.27 | -0.21 | 0.06 | 22 | ||
2014-08-07 | 2014-06-30 | -0.22 | -0.16 | 0.06 | 27 |
Cara Therapeutic Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Cara Therapeutic Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.28th of March 2024
Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights at finance.yahoo.com
26th of March 2024
After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For... at finance.yahoo.com
21st of March 2024
Kineta GAAP EPS of -1.28 beats by 0.12, revenue of 5.44M misses by 0.15M at seekingalpha.com
20th of March 2024
Acquisition by Walter Klemp of 56250 shares of Moleculin Biotech subject to Rule 16b-3 at finance.yahoo.com
14th of March 2024
Acquisition by Charles Baltic of 81500 shares of MEI Pharma at 0.225 subject to Rule 16b-3 at MacroaxisInsider
11th of March 2024
StockNews.com Initiates Coverage on Moleculin Biotech - Defense World at news.google.com
7th of March 2024
Cara Therapeutics to Host Notalgia Paresthetica Virtual KOL Event on Wednesday, March 27, ... at finance.yahoo.com
7th of March 2024
Mesoblast shareholders are up 15 percent this past week, but still in the red over the las... at simplywall.st
5th of March 2024
CARA Stock Earnings Cara Therapeutics Misses EPS, Misses Revenue for Q4 2023 at investorplace.com
5th of March 2024
KA Stock Quote Price and Forecast - CNN at news.google.com
5th of March 2024
Marinus Pharmaceuticals Reports Q4 Loss, Lags Revenue Estimates at zacks.com
29th of February 2024
Disposition of 3293 shares by Joana Goncalves of Cara Therapeutic at 0.89 subject to Rule ... at Joana Goncalves
29th of February 2024
YS Biopharma Co., Ltd. Short Interest Update - AmericanBankingNEWS at news.google.com
28th of February 2024
Form 424B5 MEI Pharma, Inc. - StreetInsider.com at news.google.com
16th of February 2024
Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Elect... at prnewswire.com
13th of February 2024
MEI Pharma GAAP EPS of -1.66 misses by 0.25 at seekingalpha.com
12th of February 2024
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx vs. SANTYL wit... at finance.yahoo.com
9th of February 2024
YS Biopharma secures 40 million in private placement at investing.com
7th of February 2024
Kineta to Participate in H.C. Wainwright Virtual Home Fireside Chat Series at benzinga.com
5th of February 2024
Acquisition by Scott Terrillion of 13500 shares of Cara Therapeutic subject to Rule 16b-3 at Scott Terrillion
30th of January 2024
Is it Time to Dump Cara Therapeutics Inc Stock After it Is Higher By 1.75 percent in a Wee... at news.google.com
30th of January 2024
Do Traders Think Mustang Bio Inc Can Keep Climbing Tuesday - InvestorsObserver at news.google.com
19th of January 2024
Brookline Capital Management Weighs in on MEI Pharma, Inc.s Q3 2024 Earnings at thelincolnianonline.com
18th of January 2024
United States Food Drug Administration Grants Mesoblast Rare Pediatric Disease Designation... at news.google.com
17th of January 2024
Kineta Provides Update on its Ongoing Phase 12 VISTA-101 Clinical Trial of KVA12123 in Pat... at finance.yahoo.com
8th of January 2024
YS Biopharma Announces Changes to its Board Committees at kalkinemedia.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cara Therapeutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cara Therapeutic's short interest history, or implied volatility extrapolated from Cara Therapeutic options trading.
Check out Cara Therapeutic Backtesting and Cara Therapeutic Hype Analysis. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Cara Stock analysis
When running Cara Therapeutic's price analysis, check to measure Cara Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cara Therapeutic is operating at the current time. Most of Cara Therapeutic's value examination focuses on studying past and present price action to predict the probability of Cara Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cara Therapeutic's price. Additionally, you may evaluate how the addition of Cara Therapeutic to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Cara Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Revenue Per Share 0.387 | Quarterly Revenue Growth (0.08) | Return On Assets (0.49) | Return On Equity (1.10) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.